Alemtuzumab

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

ID	`DRUG-ALEMTUZUMAB`
Type	Drug
Aliases	CampathLemtradaMabCampathАлемтузумаб
Status	reviewed 2026-04-26 \| pending_clinical_signoff
Diseases	`DIS-T-PLL`
Sources	`SRC-NCCN-BCELL-2025`

Drug Facts

Class	monoclonal_antibody — anti-CD52 humanized IgG1κ
Mechanism	Humanized monoclonal antibody binding CD52, a glycoprotein densely expressed on B and T lymphocytes, monocytes, NK cells, and most lymphoid malignancies. Engagement triggers antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytolysis (CDC), and direct apoptosis. Profound and prolonged depletion of CD4+ T-cells (median recovery >12 months) drives both efficacy in CD52+ malignancies (notably T-PLL) and the high opportunistic-infection burden.
Typical dosing	T-PLL: dose escalation 3 mg → 10 mg → 30 mg IV over first week to limit cytokine release; then 30 mg IV three times weekly × 12 weeks (Keating 2002). Premedicate with acetaminophen + diphenhydramine + hydrocortisone before each infusion for first 2 weeks. CLL (historical): same induction schedule; SC 30 mg three times weekly is alternative with lower infusion-reaction rate.
Ukraine registered	False
NSZU reimbursed	False
Ukraine last verified	2026-04-27

Warnings

Cytopenias — severe pancytopenia, autoimmune hemolytic anemia, ITP, pure red-cell aplasia
Infusion reactions — premedication and first-dose escalation mandatory; cytokine-release syndrome possible
Infections — CMV reactivation, PJP, HSV/VZV, fungal; antimicrobial prophylaxis required during and ≥2 months post
Malignancies — secondary thyroid cancer, melanoma, lymphoproliferative disorders

Notes

T-PLL is the principal oncologic indication retained after Campath was withdrawn from US oncology market in 2012. Mandatory infection prophylaxis: TMP-SMX (PJP), acyclovir or valacyclovir (HSV/VZV), weekly CMV PCR for the duration of therapy and ≥2 months post. Hold for ANC <250 or platelets <25K during therapy. Salvage CD52- directed therapy is being supplanted by JAK1/2 inhibitors and venetoclax-based combinations in T-PLL trials.

Used By

Contraindications

CI-ACTIVE-INFECTION-FOR-ALEMTUZUMAB - CI-ACTIVE-INFECTION-FOR-ALEMTUZUMAB

Regimens

REG-ALEMTUZUMAB-IV - Alemtuzumab IV — disease-defining anti-CD52, 12 weeks induction
REG-VENETOCLAX-ALEMTUZUMAB-TPLL - Venetoclax + alemtuzumab combination for r/r T-PLL (investigational)

Supportive Care

SUP-CMV-MONITORING - CMV PCR surveillance during T-cell-depleting therapy